EGFR and neoplasm: In addition, osimertinib-induced tumor shrinkage more markedly in patients with pIGF-1R-high expression when compared with pIGF-1R-low expression (p = 0.011) (Supplementary Figure 4c), consistent with the results of the experiments performed using EGFR-mutated NSCLC cell lines (Fig. 1a, b).